Venture Capital News Daily
   Your Source for Venture Capital and Private Equity Financings
   Massinvestor/VC News Daily      
   Venture Capital News Daily on RSS Venture Capital News Daily on Facebook Venture Capital News Daily on Twitter
VC DATABASE   /   MOBILE APP  /  CELEBRITY VCs   /   VENTURE TRACKR   /   ARCHIVE   /   ABOUT US
VC-funded Company:


Aprea Therapeutics
535 Boylston St.
Boston, MA 02116
https://www.aprea.com

Aprea Therapeutics is a Boston, Massachusetts- and Stockholm, Sweden-based biopharmaceutical company focused on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The Company's lead drug candidate is APR-246, a first-in-class small molecule in clinical development for myelodysplastic syndromes (MDS) and high-grade serious ovarian cancer, and trials in additional hematologic malignancies are planned. Aprea is also developing second generation p53 reactivators that have best-in-class potential.

Key Contact
NameTitleE-Mail
Christian S. SchadeCEOchris.schade@aprea.com


Funding Events
DateAmountTypeInvestors
11/30/18$56,600,000 5AM Ventures
HealthCap
Karolinska Development
Redmile Group  
Rock Springs Capital
Sectoral Asset Management
Versant Ventures
 
Massinvestor/VC News Daily
617-620-4606


© 2018 Massinvestor, Inc.